Skip to main content
Journal cover image

Antibacterial resistance leadership group: open for business.

Publication ,  Journal Article
Chambers, HF; Bartlett, JG; Bonomo, RA; Chiou, C; Cosgrove, SE; Cross, HR; Daum, RS; Downing, M; Evans, SR; Knisely, J; Kreiswirth, BN ...
Published in: Clin Infect Dis
June 2014

Funded by the National Institute of Allergy and Infectious Diseases, the Antibacterial Resistance Leadership Group (ARLG) is tasked with developing a clinical research agenda and conducting clinical studies to address the growing public health threat of antibacterial resistance. The ARLG has identified 4 high-priority areas of research: infections caused by gram-negative bacteria, infections caused by gram-positive bacteria, antimicrobial stewardship and infection prevention, and diagnostics. The ARLG will be accepting proposals from the scientific community for clinical research that addresses 1 or more of these high-priority areas. These studies should have the potential to transform medical practice and be unlikely to occur without ARLG support. The purpose of this article is to make interested parties aware of clinical research opportunities made available by ARLG and to encourage submission of clinical research proposals that address the problem of antibacterial resistance.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

June 2014

Volume

58

Issue

11

Start / End Page

1571 / 1576

Location

United States

Related Subject Headings

  • United States
  • National Institute of Allergy and Infectious Diseases (U.S.)
  • Microbiology
  • Leadership
  • Humans
  • Drug Utilization
  • Drug Resistance, Bacterial
  • Capital Financing
  • Biomedical Research
  • Bacterial Infections
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Chambers, H. F., Bartlett, J. G., Bonomo, R. A., Chiou, C., Cosgrove, S. E., Cross, H. R., … Fowler, V. G. (2014). Antibacterial resistance leadership group: open for business. Clin Infect Dis, 58(11), 1571–1576. https://doi.org/10.1093/cid/ciu132
Chambers, Henry F., John G. Bartlett, Robert A. Bonomo, Christine Chiou, Sara E. Cosgrove, Heather R. Cross, Robert S. Daum, et al. “Antibacterial resistance leadership group: open for business.Clin Infect Dis 58, no. 11 (June 2014): 1571–76. https://doi.org/10.1093/cid/ciu132.
Chambers HF, Bartlett JG, Bonomo RA, Chiou C, Cosgrove SE, Cross HR, et al. Antibacterial resistance leadership group: open for business. Clin Infect Dis. 2014 Jun;58(11):1571–6.
Chambers, Henry F., et al. “Antibacterial resistance leadership group: open for business.Clin Infect Dis, vol. 58, no. 11, June 2014, pp. 1571–76. Pubmed, doi:10.1093/cid/ciu132.
Chambers HF, Bartlett JG, Bonomo RA, Chiou C, Cosgrove SE, Cross HR, Daum RS, Downing M, Evans SR, Knisely J, Kreiswirth BN, Lautenbach E, Mickley BS, Patel R, Pettigrew MM, Rodvold KA, Spellberg B, Fowler VG. Antibacterial resistance leadership group: open for business. Clin Infect Dis. 2014 Jun;58(11):1571–1576.
Journal cover image

Published In

Clin Infect Dis

DOI

EISSN

1537-6591

Publication Date

June 2014

Volume

58

Issue

11

Start / End Page

1571 / 1576

Location

United States

Related Subject Headings

  • United States
  • National Institute of Allergy and Infectious Diseases (U.S.)
  • Microbiology
  • Leadership
  • Humans
  • Drug Utilization
  • Drug Resistance, Bacterial
  • Capital Financing
  • Biomedical Research
  • Bacterial Infections